Evidence map›Paper›PMID 34575173›Full record

ReviewJournal of clinical medicine2021

Catheter Ablation in Persistent AF, the Evolution towards a More Pragmatic Strategy.

Louisa O'Neill, Jean-Yves Wielandts, Kris Gillis, Gabriela Hilfiker, Jean-Benoit Le Polain De Waroux, Rene Tavernier, Mattias Duytschaever, Sebastien Knecht

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. EFFECTS OF TORSO IMPEDANCE ON IN SILICO VOLTAGE MAPPING OF CARDIAC DIPOLES OF ROTORS.Annual Modeling and Simulation Conference (ANNSIM). Annual Modeling and Simulation Conference (Online) · 2025
    Article
  4. Article
  5. Extracellular Vesicles and Thrombogenicity in Atrial Fibrillation.International journal of molecular sciences · 2022
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Louisa O'NeillDepartment of Cardiology, AZ Sint-Jan Hospital, 8200 Bruges, Belgium.
Jean-Yves WielandtsDepartment of Cardiology, AZ Sint-Jan Hospital, 8200 Bruges, Belgium.
Kris GillisDepartment of Cardiology, AZ Sint-Jan Hospital, 8200 Bruges, Belgium.
Gabriela HilfikerDepartment of Cardiology, AZ Sint-Jan Hospital, 8200 Bruges, Belgium.
Jean-Benoit Le Polain De WarouxDepartment of Cardiology, AZ Sint-Jan Hospital, 8200 Bruges, Belgium.ORCID 0000-0003-1737-1353
Rene TavernierDepartment of Cardiology, AZ Sint-Jan Hospital, 8200 Bruges, Belgium.
Mattias DuytschaeverDepartment of Cardiology, AZ Sint-Jan Hospital, 8200 Bruges, Belgium.
Sebastien KnechtDepartment of Cardiology, AZ Sint-Jan Hospital, 8200 Bruges, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide and represents a heterogeneous disorder with a complex pathological basis. While significant technological advances have taken place over the last decade in the field of catheter ablation of AF, response to ablation varies and long-term success rates in those with persistent AF remain modest. Mechanistic studies have highlighted potentially different sustaining factors for AF in the persistent AF population with substrate-driven focal and re-entrant sources in the body of the atria identified on invasive and non-invasive mapping studies. Translation to clinical practice, however, remains challenging and the application of such mapping techniques to clinical ablation has yet to demonstrate a significant benefit beyond pulmonary vein isolation (PVI) alone in the persistent AF cohort. Recent advances in catheter and ablation technology have centered on improving the durability of ablation lesions at index procedure and although encouraging results have been demonstrated with early studies, large-scale trials are awaited. Further meaningful improvement in clinical outcomes in the persistent AF population requires ongoing advancement in the understanding of AF mechanisms, coupled with continuing progress in catheter technology capable of delivering durable transmural lesions.

Indexed as

AF mappingnovel ablation technologypersistent AFpulmonary vein isolationsubstrate ablation

Identifiers

PMID34575173
PMCPMC8467025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.